The Current PRF market is 54 million in 2024. The PRF market is expected to grow as the bone graft and implants market grows because PRF is used with bone grafts at bony defects, including sites that could undergo future dental implant placement.

The global dental bone graft market is expected to reach $1.4 billion by 2030, growing at a CAGR of 9.5% from 2023 to 2030 ¹. Source

The global dental implants market was valued at $4.99 billion in 2023 and is expected to reach $9.62 billion by 2030, growing at a CAGR of 9.8% from 2024 to 2030 ¹. Source

Current device deficiencies and needs of a safer PRF are solved with our unique patented devices to comply with the PRF blood components laws and federal regulations for:
1-Sterility of blood tubes to avoid PRF contamination risks
2-Plain tubes without additives or coats
3- No glass tubes unless protected with puncture-resistant material. OSHA GLASS TUBES LAW.
4- OSHA law mandates replacement for new safer medical devices.
Patent granted to Biomedical RGF and patents pending globally for exclusivity for 20 years or more. New pending patents in progress.

Great returns are expected in the first year after FDA clearance, which is scheduled for fall 2026.
Exit strategies include:
1- Partner with a dental implants or medical device company
2- Go to market, generating substantive returns
3- Go public after three years

An additional option is to explore patent licensing to dental implants and medical device companies.

Our PRF-BRGF system is the new standard of care for Platelet-Rich Fibrin (PRF), offering a safer solution to current PRF challenges, including contamination risks, user and patient safety, and compliance issues.

PRF is used in invasive surgery. The FDA and OSHA’s Bloodborne Pathogens Standard (29 CFR 1910.1030) requires employers to annually identify, evaluate, and implement safer medical devices designed to reduce injury and risks, and to reduce or eliminate worker exposure.

Unique, innovative, safer PRF devices. Patented technology and continuous performance testing, Bio-compatibility, sterility, and endobacterial batch testing to ensure blood/plasma purity, safety, and compliance.
Safer PRF with unbeatable Low-cost supplies to doctors.
The PRF-BRGF system is a safer PRF system that complies with the FDA and all federal regulations for blood purity, safety, and sterility to avoid PRF contamination, User injury, and Doctors’ liability risks. New patents to further protect our PRF system innovation components.

Required medical device bench lab tests have taken time and more funds, as is normal in the medical device industry.

Biomedical Regenerative is a startup company offering a private investment opportunity. Biocompatibility, performance and sterility tests are completed.

We are working on the final stages of EMC & electrical safety tests to obtain FDA clearance and enter the USA market, which is expected by the end of the third quarter of 2026.